Lumateperone high dose
Phase 3
Lumateperone high dose is one of 4 therapeutic programs targeting Irritability Associated With Autism Spectrum Disorder. It is currently in Phase 3.
1
Indications
2
Total Trials
2
Active Trials
3
Competitors
Pipeline
Status by Indication[2][1]
Indication
Competition
Competitive Landscape
4 competitors in Irritability Associated With Autism Spectrum Disorder
#DrugCompanyPhaseTrials
1Karxt
Bristol-Myers SquibbPhase 3
Karx-EC
Bristol-Myers SquibbPhase 3
Lumateperone high dose
IIntra-Cellular Therapies, Inc.
Phase 3
Lumateperone Low Dose
IIntra-Cellular Therapies, Inc.
Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Irritability Associated With Autism Spectrum Disorder2 trials
Sources
References
- [1]
- [2]Open Targets Platform — Drug–disease associations for Lumateperone high dose. EMBL-EBI & Wellcome Sanger Institute.
- [3]
Details
Drug Info
Quick Facts
- Highest Phase
- Phase 3[1]
- Company
- IIntra-Cellular Therapies, Inc.